197 related articles for article (PubMed ID: 20664931)
1. Effects of lentinan alone and in combination with fluoropyrimidine anticancer agent on growth of human oral squamous cell carcinoma in vitro and in vivo.
Harada K; Itashiki Y; Takenawa T; Ueyama Y
Int J Oncol; 2010 Sep; 37(3):623-31. PubMed ID: 20664931
[TBL] [Abstract][Full Text] [Related]
2. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
3. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
4. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.
Ferdous T; Harada K; Kin T; Harada T; Ueyama Y
Int J Oncol; 2013 Jul; 43(1):271-9. PubMed ID: 23695365
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells.
Tamatani T; Ferdous T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Nagai H; Fujisawa K; Miyamoto Y
Int J Oncol; 2012 Sep; 41(3):1148-56. PubMed ID: 22766915
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1.
Harada K; Kawashima Y; Yoshida H; Sato M
Oncol Rep; 2006 Jun; 15(6):1417-23. PubMed ID: 16685374
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
[TBL] [Abstract][Full Text] [Related]
9. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models.
Li JA; Xu XF; Han X; Fang Y; Shi CY; Jin DY; Lou WH
Pancreas; 2016 Mar; 45(3):425-33. PubMed ID: 26495780
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of honokiol and 5-fluorouracil on apoptosis of oral squamous cell carcinoma cells.
Ji N; Jiang L; Deng P; Xu H; Chen F; Liu J; Li J; Liao G; Zeng X; Lin Y; Feng M; Li L; Chen Q
J Oral Pathol Med; 2017 Mar; 46(3):201-207. PubMed ID: 27465776
[TBL] [Abstract][Full Text] [Related]
11. Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy.
Tateishi Y; Tatemoto Y; Ohno S; Morishita K; Ueta E; Yamamoto T
Cancer Lett; 2009 Feb; 274(2):187-93. PubMed ID: 18986760
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells.
Harada K; Kawaguchi S; Supriatno ; Onoue T; Yoshida H; Sato M
Oral Oncol; 2004 Aug; 40(7):713-9. PubMed ID: 15172641
[TBL] [Abstract][Full Text] [Related]
13. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
[TBL] [Abstract][Full Text] [Related]
14. Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma.
Harada K; Ferdous T; Yoshida H
Oncol Rep; 2007 Nov; 18(5):1077-83. PubMed ID: 17914556
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of S-1 plus cisplatin combination neoadjuvant chemotherapy in patients with oral cancer.
Kawasaki G; Yoshitomi I; Yanamoto S; Yamada S; Mizuno A
Gan To Kagaku Ryoho; 2011 Jun; 38(6):951-7. PubMed ID: 21677485
[TBL] [Abstract][Full Text] [Related]
16. The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma.
Yamashita T; Toida M; Kato K; Long NK; Miyazaki Y; Asaka Y; Hatakeyama D; Yonemoto K; Makita H; Kato Y; Shibata T
Oncol Rep; 2009 Sep; 22(3):501-7. PubMed ID: 19639195
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines.
Harada K; Ferdous T; Kobayashi H; Ueyama Y
Int J Oncol; 2014 Dec; 45(6):2439-45. PubMed ID: 25230791
[TBL] [Abstract][Full Text] [Related]
18. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
[TBL] [Abstract][Full Text] [Related]
19. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
